Monte Rosa Q3 net income $3.1 million, up from $27.1 million loss a year earlier
Monte Rosa Therapeutics reported third-quarter 2026 results, with collaboration revenue of $54.4 million and net income of $3.1 million, compared with $12.8 million of revenue and a $27.1 million net loss a year earlier. The revenue increase was mainly driven by a $50.0 million Novartis milestone, and the company's nine-month results still show a net loss of $84.8 million.
Key points
- Q3 2026 collaboration revenue was $54.4 million, versus $12.8 million in Q3 2025, primarily from a $50.0 million milestone tied to Novartis's Phase 2 study of MRT-6160 in Sjögren's disease.
- Q3 2026 R&D expenses were $45.4 million, up from $36.7 million, mainly from increased spending on development and discovery programs.
- Nine-month 2026 net loss was $84.8 million, compared with net income of $7.5 million in the first nine months of 2025.
- Cash, cash equivalents, restricted cash, and marketable securities were $582.6 million as of September 30, 2026, which the company expects to support operations into 2029.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.